National Jewish Health will be able to help basic scientists and clinical researchers pursue new cures and treatments through its Translational Research Initiative, thanks to a $200,000 grant from the Feil Family Trust.
Translational research provides a bridge from discovery to delivery, taking findings from the lab to the patient’s bedside. The National Jewish Health Translational Research Initiative strives to bring together basic scientists and clinicians to begin projects that might not be possible without collaboration.
Each year, National Jewish Health sets aside $200,000 for hand-selected research projects that allow scientist-and-physician teams to start their research and obtain preliminary data. With that “seed money,” researchers create a framework for applications for larger funding agencies, including the National Institutes of Health.
This year’s selected projects will research:
- The cause and possibly more effective treatment of a common infection in patients with cystic fibrosis.
- A type of enzyme that is important for the development of lung cancer. By studying this enzyme, researchers may be able identify new treatment options for lung cancer.
- A novel approach to studying B-cell deficiencies, which impact how effectively a person’s immune system responds to infection.
- The establishment of the Lung Mucosal Immunity Program, which aims to bring together scientists and physicians from across the institution who are studying lung mucosal immunity. Lung mucosa help defend against many lung diseases, including asthma, COPD, lung cancer, allergy and immune conditions.
Thank you to the Feil Family Trust for this generous grant. Please look for updates on the Translational Research Initiative in future issues of Health-e-News.
Learn more about how you can support patients at National Jewish Health